An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

NCT02286362 · clinicaltrials.gov ↗
COMPLETED
Status
510
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Hoffmann-La Roche